First promising results on a pilot experience suggest that a single course of tandem therapy with low-activity 225Ac-PSMA-617/full-activity 177Lu-PSMA-617 may safely enhance response to PRLT in men with late-stage/end-stage metastatic castration-resistant prostate cancer while minimizing xerostomia severity.